The impact of drug-drug interactions on pulmonary arterial hypertension therapy.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pulmonary Pharmacology & Therapeutics

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pupt.2014.01.004PMID 24462771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.

  2013cited by this paper
• Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

  2013cited by this paper
• Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.

  2013cited by this paper
• Riociguat for the treatment of pulmonary arterial hypertension.

  2013cited by this paper
• Evolving epidemiology of pulmonary arterial hypertension.

  2012cited by this paper
• Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors.

  2012cited by this paper
• Current Management of Primary Pulmonary Hypertension

  2012cited by this paper
• Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

  2012cited by this paper
• Current Management of Primary Pulmonary Hypertension

  2012cited by this paper
• Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes.

  2012cited by this paper
• Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians

  2012cited by this paper
• Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

  2011cited by this paper
• Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far

  2011cited by this paper
• Effects of Multiple Doses of Ambrisentan on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Volunteers

  2011cited by this paper
• Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study

  2011cited by this paper
• Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

  2010cited by this paper
• Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

  2010cited by this paper
• Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan

  2009cited by this paper
• Development and pathology of pulmonary hypertension.

  2009cited by this paper
• Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension

  2009cited by this paper
• Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

  2009cited by this paper
• Drug Interactions in Pulmonary Arterial Hypertension and Their Implications

  2009cited by this paper
• Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects

  2007cited by this paper
• Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

  2007cited by this paper
• Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

  2007cited by this paper
• Role of OATP transporters in the disposition of drugs.

  2007cited by this paper
• AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN

  2006cited by this paper
• Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.

  2006cited by this paper
• Evaluation and Management of the Patient with Pulmonary Arterial Hypertension

  2005cited by this paper
• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

  2005cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.

  2004cited by this paper
• Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

  2004cited by this paper
• Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

  2004cited by this paper
• Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions

  2004cited by this paper
• Prostanoid therapy for pulmonary arterial hypertension.

  2004cited by this paper
• Deprescribing: Achieving Better Health Outcomes for Older People through Reducing Medications

  2003cited by this paper
• Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

  2002cited by this paper
• Implications of cytochrome P450 interactions when prescribing medication for hypertension.

  2002cited by this paper
• The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions

  2001cited by this paper
• CYP3A genetics in drug metabolism

  2001cited by this paper
• Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension.

  2001cited by this paper
• Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.

  2000cited by this paper
• Drug Interaction Facts

  1990cited by this paper

• Depression in Pulmonary Hypertension: A Systematic Review of Clinical Outcomes, Treatment Interactions, and Emerging Technologies

  2025cites this paper
• Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH.

  2024cites this paper
• Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study

  2022influential citation
• Pharmacotherapeutic approach toward urological medications and vaccination during COVID-19: a narrative review

  2021cites this paper
• Pharmacological interactions: Synergism, or not synergism, that is the question

  2021cites this paper
• Cardiac Considerations in Chronic Lung Disease

  2020cites this paper
• Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.

  2020cites this paper
• Medication Safety in Chronic Lung Disease with Cardiac Comorbidity

  2020cites this paper
• Praliciguat. Soluble guanylate cyclase activator, Treatment of heart failure with preserved ejection fraction, Treatment of diabetic nephropathy

  2019cites this paper
• Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?

  2019cites this paper
• Enzyme-mediated dual-targeted-assembly realizes a synergistic anticancer effect.

  2019cites this paper
• In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein

  2018influential citation
• Pulmonary Arterial Hypertension: Pathophysiology and Treatment

  2018cites this paper
• The Complexity of Characteristics, Diagnoses and Treatment of Older Patients With Pulmonary Hypertension

  2018cites this paper
• Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

  2018cites this paper
• Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

  2018cites this paper
• Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities

  2017cites this paper
• Characterization of potassium channels involved in the mechanisms of vascular relaxation induced by omega‐3 polyunsaturated fatty acids in rat arteries; a critical role for KATP channels

  2017cites this paper
• Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU

  2016cites this paper
• Metabolism study and biological evaluation of bosentan derivatives.

  2016cites this paper
• Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU

  2016cites this paper
• Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review

  2015cites this paper
• New pharmacotherapy options for pulmonary arterial hypertension

  2015influential citation
• Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

  2015cites this paper
• Ambrisentan: a guide to its use in pulmonary arterial hypertension in the EU

  2014cites this paper
• Current clinical management of pulmonary arterial hypertension.

  2014cites this paper